Business Context and Reporting Period
This Form 8-K was filed by Zafgen, Inc. on February 12, 2019. The report details the entry into a material definitive agreement regarding the company's headquarters. Note: The request metadata references "Larimar Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Zafgen, Inc.
Key Financial Metrics and Obligations
The filing discloses a new long-term lease obligation rather than operational financial results (revenue, profit, or cash flow).
- Asset: Approximately 17,705 square feet of office space at 1-3 Center Plaza, Boston, Massachusetts.
- Term: 124 months (approximately 10 years and 4 months).
- Commencement: Lease payments begin 4 months after the delivery of the premises.
- Initial Rent: $82,623.33 per month in Year 1.
- Final Rent: $95,902.08 per month in Year 10.
- Additional Costs: Company is responsible for its share of operating expenses and taxes.
- Extension Option: Option to extend the term for an additional 60 months.
Material Changes
The primary material change is the execution of the Office Lease Agreement on February 12, 2019, establishing a new direct financial obligation for the company's headquarters. The filing does not provide comparative financial data against prior periods as it is a current report on a specific event.
Outlook, Risks, and Management Commentary
The filing incorporates the lease details into Item 2.03 regarding the creation of a direct financial obligation. The agreement includes customary representations, warranties, covenants, and mutual indemnities. The full text of the lease is intended to be filed as an exhibit to the Annual Report on Form 10-K for the year ended December 31, 2018. No specific guidance, risks, or unusual items beyond the lease terms are disclosed in this document.
Investor Verification Checklist
- Verify the exact "Commencement Date" to determine when the 4-month rent abatement period ends.
- Review the full lease agreement (to be filed in the 10-K) for specific definitions of "operating expenses" and tax responsibilities.
- Confirm the company's current liquidity position to ensure it can meet the escalating rent schedule over the 124-month term.
- Clarify the discrepancy between the request metadata (Larimar Therapeutics) and the filing registrant (Zafgen, Inc.).